-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pancreatic cancer (PDAC) will affect 60,430 people in the United States and is the third leading cause of death from malignancies, with a 5-year survival rate that has improved to 10%
Pancreatic cancer (PDAC) will affect 60,430 people in the United States and is the third leading cause of death from malignancies, with a 5-year survival rate that has improved to 10%
A total of 4626 patients met the inclusion criteria, including 1542 PDAC and 3084 controls; median age was 69.
This study shows that patients with elevated blood glucose and weight loss predate the diagnosis of PDAC, and these metabolic changes may indicate an underlying PDAC incidence
This study shows that patients with elevated blood glucose and weight loss predate the diagnosis of PDAC, and these metabolic changes may indicate an underlying PDAC incidence
Original source:
Marlon J.
Marlon J.
Brewer.
Et al.
Glycemic Changes and Weight Loss Precede Pancreatic Ductal Adenocarcinoma by up to 3 Years in a Diverse Population.
Clinical Gastroenterology and Hepatology.
2022.
Glycemic Changes and Weight Loss Precede Pancreatic Ductal Adenocarcinoma by up to 3 Years in a Diverse Population.
Leave a comment here